CA Patent

CA2843885C — Vitamin b6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates

Assigned to MBC PHARMA Inc · Expires 2020-03-10 · 6y expired

What this patent protects

Compounds, compositions, and methods of using them to treat infections, neoplastic disease, inflammatory disease, and pain. Such compounds are nucleotides, acydonucleotides, and acydic nucleoside phosphonates (ANP) phosphonates conjugated with forms and/or moieties of Vitamin B6 …

USPTO Abstract

Compounds, compositions, and methods of using them to treat infections, neoplastic disease, inflammatory disease, and pain. Such compounds are nucleotides, acydonucleotides, and acydic nucleoside phosphonates (ANP) phosphonates conjugated with forms and/or moieties of Vitamin B6 for delivery past the cell membrane and into the cell. Methods of delivering nucleotides, acydonucleotide and ANPs to the inside of the cell by conjugating said compounds with forms and/or moieties of Vitamin B6.

Drugs covered by this patent

Patent Metadata

Patent number
CA2843885C
Jurisdiction
CA
Classification
—
Expires
2020-03-10
Drug substance claim
No
Drug product claim
No
Assignee
MBC PHARMA Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.